Do the results of OptiTROP-Lung04 change your management of patients with TKI-resistant EGFR mutated advanced NSCLC?

What concerns, if any, do you have with implementing Sacituzumab tirumotecan (sac-TMT)? Fang et al., PMID: 41124220